Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes
- PMID: 35922801
- PMCID: PMC9351095
- DOI: 10.1186/s12916-022-02453-7
Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes
Abstract
Background: Prostate cancer is an epidemic of the modern age, and despite efforts to improve awareness, it remains the case that mortality has hardly altered over the decades, driven largely by late presentation. There is a strong public perception that male urinary symptoms is one of the key indicators of prostate cancer, and this continues to be part of messaging from national guidelines and media health campaigns. This narrative, however, is not based on evidence and may be seriously hampering efforts to encourage early presentation.
Discussion: Anatomically, prostate cancer most often arises in the peripheral zone, while urinary symptoms result from compression of the urethra by prostatic enlargement more centrally. Biopsy studies show that mean prostate volume is actually lower in men found to have (early) prostate cancer compared to those with benign biopsies. This inverse relationship between prostate size and the probability of cancer is so strong that PSA density (PSA corrected for prostate volume) is known to be significantly more accurate in predicting a positive biopsy than PSA alone. Thus, this disconnect between scientific evidence and the current perception is very striking. There is also evidence that using symptoms for investigating possible cancer may lead to higher proportions of men presenting with locally advanced or metastatic disease compared to PSA testing or screening programmes. Concerns about overwhelming health care services if men are encouraged to get tested without symptoms may also be overstated, with recent newer approaches to reduce over-investigation and treatment. In this article, we explore the link between urinary symptoms and prostate cancer and propose that public and professional messaging needs to change.
Conclusion: If rates of earlier diagnosis are to improve, we call for strong clear messaging that prostate cancer is a silent disease especially in the curable stages and men should come forward for testing regardless of whether or not they have symptoms. This should be done in parallel with other ongoing efforts to raise awareness including targeting men at highest risk due to racial ancestry or family history. While the current resurgence in interest and debate about prostate cancer screening is timely, change of this message by guideline bodies, charities and the media can be a first simple step to improving earlier presentation and hence cures rates.
Keywords: Early detection; Lower urinary tract symptoms; Prostate cancer; Symptoms.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
PSA testing for men at average risk of prostate cancer.Public Health Res Pract. 2017 Jul 26;27(3):2731721. doi: 10.17061/phrp2731721. Public Health Res Pract. 2017. PMID: 28765854
-
Prostate cancer screening practices in a large, integrated health system: 2007-2014.BJU Int. 2017 Aug;120(2):257-264. doi: 10.1111/bju.13793. Epub 2017 Feb 26. BJU Int. 2017. PMID: 28139034 Free PMC article.
-
The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.BJU Int. 2012 Sep;110(5):638-43. doi: 10.1111/j.1464-410X.2012.10962.x. Epub 2012 Apr 30. BJU Int. 2012. PMID: 22540895 Free PMC article. Clinical Trial.
-
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519. BMJ. 2018. PMID: 30185521 Free PMC article.
-
[Advancements in PSA-based screening for prostate cancer].Rinsho Byori. 2004 Jul;52(7):611-7. Rinsho Byori. 2004. PMID: 15344561 Review. Japanese.
Cited by
-
The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.Clin Transl Oncol. 2023 Feb;25(2):352-363. doi: 10.1007/s12094-022-02957-x. Epub 2022 Oct 6. Clin Transl Oncol. 2023. PMID: 36203075 Free PMC article. Review.
-
How a population-based cohort of men estimate lifetime risk of prostate cancer in a survey before entering a prostate cancer screening trial in Sweden?BMJ Open. 2024 Aug 17;14(8):e083562. doi: 10.1136/bmjopen-2023-083562. BMJ Open. 2024. PMID: 39153780 Free PMC article.
-
Symptom appraisal and help seeking in males with symptoms of possible prostate cancer: a qualitative study with an ethnically diverse sample in London.Br J Gen Pract. 2023 Jun 29;73(732):e502-e510. doi: 10.3399/BJGP.2022.0554. Print 2023 Jul. Br J Gen Pract. 2023. PMID: 37253629 Free PMC article.
-
Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review.Cancers (Basel). 2025 Jun 25;17(13):2137. doi: 10.3390/cancers17132137. Cancers (Basel). 2025. PMID: 40647437 Free PMC article. Review.
-
Genetically predicted benign prostate hyperplasia causally affects prostate cancer: a two-sample Mendelian randomization.Transl Androl Urol. 2025 Mar 30;14(3):661-668. doi: 10.21037/tau-2024-673. Epub 2025 Mar 26. Transl Androl Urol. 2025. PMID: 40226058 Free PMC article.
References
-
- Adams J. The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet. 1853;1:393–394.
-
- Barrett T, Slough R, Sushentsev N, Shaida N, Koo BC, Caglic I, Kozlov V, Warren AY, Thankappannair V, Pinnock C, Shah N, Saeb-Parsy K, Gnanapragasam VJ, Sala E, Kastner C. Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways. Clin Radiol. 2019;74(11):894.e1–894.e9. doi: 10.1016/j.crad.2019.06.004. - DOI - PubMed
-
- Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous